ATE443259T1 - Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests - Google Patents

Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests

Info

Publication number
ATE443259T1
ATE443259T1 AT02761799T AT02761799T ATE443259T1 AT E443259 T1 ATE443259 T1 AT E443259T1 AT 02761799 T AT02761799 T AT 02761799T AT 02761799 T AT02761799 T AT 02761799T AT E443259 T1 ATE443259 T1 AT E443259T1
Authority
AT
Austria
Prior art keywords
circulative
antigens
antigen
determination
therapeutic antibodies
Prior art date
Application number
AT02761799T
Other languages
English (en)
Inventor
Maher Albitar
Michael Keating
Taghi Manshouri
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE443259T1 publication Critical patent/ATE443259T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/809—Multifield plates or multicontainer arrays
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
AT02761799T 2001-09-20 2002-09-20 Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests ATE443259T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32367901P 2001-09-20 2001-09-20
PCT/US2002/030142 WO2003024993A2 (en) 2001-09-20 2002-09-20 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays

Publications (1)

Publication Number Publication Date
ATE443259T1 true ATE443259T1 (de) 2009-10-15

Family

ID=23260258

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02761799T ATE443259T1 (de) 2001-09-20 2002-09-20 Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests

Country Status (8)

Country Link
US (10) US7718387B2 (de)
EP (2) EP2131198B1 (de)
JP (4) JP4424987B2 (de)
AT (1) ATE443259T1 (de)
AU (1) AU2002327037A1 (de)
DE (1) DE60233744D1 (de)
HK (1) HK1068411A1 (de)
WO (1) WO2003024993A2 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762032B1 (en) * 1999-08-23 2004-07-13 Biocrystal, Ltd. Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response
ES2267593T3 (es) * 2000-02-16 2007-03-16 Genentech, Inc. Anticuerpos anti-april y celulas hibridomas.
MXPA04001050A (es) * 2001-08-03 2004-07-08 Genentech Inc Polipeptidos tacis y br3 y usos de los mismos.
ATE443259T1 (de) * 2001-09-20 2009-10-15 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
CA2492447A1 (en) * 2002-07-25 2004-02-05 Genentech, Inc. Taci antibodies and uses thereof
EP1944320A1 (de) * 2002-12-16 2008-07-16 Genentech, Inc. Immunglobulinvarianten und Verwendungen davon
BRPI0411276A (pt) * 2003-06-05 2006-08-01 Genentech Inc métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
US20050032130A1 (en) * 2003-07-29 2005-02-10 Genentech, Inc. Neutralizing antibody assay and uses therefor
WO2005023302A2 (en) * 2003-08-29 2005-03-17 Genentech, Inc. Anti-cd20 therapy of ocular disorders
US20050069958A1 (en) * 2003-09-26 2005-03-31 Mills Rhonda A. Method for simultaneous evaluation of a sample containing a cellular target and a soluble analyte
EP2198875A1 (de) * 2003-10-24 2010-06-23 Nora, LLC Verfahren zur Reduzierung der Wahrscheinlichkeit von Frühwehen bei einer Person, die darauf angewiesen ist
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
US20090226397A1 (en) * 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
WO2005045058A2 (en) * 2003-10-27 2005-05-19 Monogram Biosciences, Inc. Detecting human anti-therapeutic antibodies
AU2004303848A1 (en) * 2003-12-19 2005-07-07 Genentech, Inc. Detection of CD20 in transplant rejection
US20050186206A1 (en) * 2003-12-19 2005-08-25 Genentech, Inc. Detection of CD20 in therapy of autoimmune diseases
ZA200608982B (en) * 2004-05-05 2008-06-25 Genentech Inc Preventing autoimmune disease by using an anti-CD20 antibody
NZ604082A (en) * 2004-06-04 2014-09-26 Genentech Inc Method for treating multiple sclerosis
US20060024295A1 (en) * 2004-06-04 2006-02-02 Genentech, Inc. Method for treating lupus
EP1781378A2 (de) * 2004-07-22 2007-05-09 Genentech, Inc. Verfahren zur behandlung des sjögren-syndroms
US20060024744A1 (en) * 2004-07-28 2006-02-02 Mills Rhonda A Methods for substantially simultaneous evaluation of a sample containing a cellular target and a soluble analyte
EP1812060A2 (de) * 2004-10-05 2007-08-01 Genentech, Inc. Verfahren zur behandlung von vaskulitis
EP1645284A1 (de) * 2004-10-08 2006-04-12 Charité - Universitätsmedizin Berlin Verwendung von CDw52-Liganden zur Behandlung von Erkrankungen, die auf degenerierten Makrophagen basieren
MX2007006895A (es) * 2004-12-23 2007-06-26 Hoffmann La Roche Deteccion de un anticuerpo terapeutico en animal de experimentacion.
CN101102793A (zh) * 2005-01-13 2008-01-09 健泰科生物技术公司 治疗方法
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
KR20080046135A (ko) * 2005-05-20 2008-05-26 제넨테크, 인크. 자가면역 질환 대상체로부터의 생물학적 샘플의 예비처리
MY157955A (en) * 2005-07-06 2016-08-30 Hoffmann La Roche Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
US20070042443A1 (en) * 2005-08-17 2007-02-22 Quest Diagnostics Investments Incorporated Hematopoietic cell phenotyping using free circulating cellular markers
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
JP6088723B2 (ja) * 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
DE102006012613B4 (de) * 2006-03-17 2010-01-14 Mpb Meltec Patent- Und Beteiligungsgesellschaft Mbh Verfahren zur Bestimmung der therapeutischen Wirksamkeit von Substanzen
US20100021424A1 (en) * 2006-06-02 2010-01-28 Vincent Brichard Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy
US20100041063A1 (en) * 2006-09-12 2010-02-18 Ulrich Essig Anti-drug antibody assay
US20120269774A1 (en) * 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
DK3597659T3 (da) 2007-07-09 2023-04-03 Genentech Inc Forhindring af disulfidbindingsreduktion under rekombinant produktion af polypeptider
ES2565202T3 (es) 2007-10-16 2016-04-01 Zymogenetics, Inc. Combinación de activador transmembrana y modulador de calcio e interactor de ligando de ciclofilina (TACI) y agentes anti-CD20 para tratamiento de enfermedades autoinmunitarias
WO2009058363A1 (en) * 2007-11-02 2009-05-07 The Trustrees Of Columbia University In The City Of New York Antibody to rage and uses for in vivo imaging or for targeting therapy
EP2246702B1 (de) 2007-12-03 2015-10-07 Tamagawa Seiki Co., Ltd. Biosensing-verfahren unter verwendung beschichteter magnetischer mikropartikel und bei dem verfahren zu verwendende biosensing-vorrichtung
EP2077281A1 (de) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US11051733B2 (en) * 2008-01-18 2021-07-06 Wake Forest University Health Sciences Isolating and purifying cells for therapy
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
ES2793348T3 (es) 2009-08-11 2020-11-13 Hoffmann La Roche Producción de proteínas en medios de cultivo celular libres de glutamina
US20110195439A1 (en) * 2010-02-10 2011-08-11 Selinfreund Richard H Systems and methods for determining cardiac conditions
JP5841072B2 (ja) 2010-02-10 2016-01-06 イミュノジェン・インコーポレーテッド Ｃｄ２０抗体およびその使用
WO2012022682A1 (en) 2010-08-17 2012-02-23 F. Hoffmann-La Roche Ag Anti-human igg1 antibody
WO2012159045A1 (en) * 2011-05-19 2012-11-22 Baxter International Inc. Detection of circulating adamts13-antibody complexes
EP2761294B1 (de) 2011-09-29 2019-02-27 Meso Scale Technologies, LLC Biodosimetriepanelle und verfahren
BR112014011758A2 (pt) 2011-11-15 2017-05-09 The Walter And Eliza Hall Inst Of Medical Res composição farmacêutica, proteína de fusão, polinucleotídeo, vetor, célula isolada, métodos para produzir uma proteína de fusão, para tratar ou previnir uma doença ou condição, para diagnosticar a suscetibilidade de um indivíduo a desenvolver uma doença ou condição, para determinar uma adequabilidade do indivíduo para ingressar em um experimento de classificação dedroga, e para identificar um agente, uso de uma combinação, e, combinação.
EP2676966A1 (de) * 2012-06-19 2013-12-25 Biouniversa S.r.l. BAG3 als biochemisches Serum und Gewebemarker
RU2636822C2 (ru) 2012-07-13 2017-11-28 Ф.Хоффманн-Ля Рош Аг Способ обнаружения мультиспецифического связывающего агента
EP2885639B1 (de) 2012-08-17 2019-04-10 MorphoSys AG Komplexspezifische antikörper und antikörperfragmente und ihre verwendung
SG11201503843VA (en) * 2012-11-15 2015-06-29 Inst Medical W & E Hall Soluble mediator
WO2015160834A1 (en) * 2014-04-14 2015-10-22 Abreos Biosciences, Inc. Lateral flow immunoassay
CN104360057B (zh) * 2014-10-22 2016-10-05 上海泰因生物技术有限公司 一种检测抗cd52抗体的elisa反应体系与方法
JP6407694B2 (ja) * 2014-12-16 2018-10-17 株式会社日立ハイテクノロジーズ プラズマ処理装置
WO2016198835A1 (en) 2015-06-08 2016-12-15 Arquer Diagnostics Limited Methods and kits
US11519916B2 (en) 2015-06-08 2022-12-06 Arquer Diagnostics Limited Methods for analysing a urine sample
RS62986B1 (sr) 2015-06-24 2022-03-31 Hoffmann La Roche Antitela na transferinski receptor sa prilagođenim afinitetom
CN104965076B (zh) * 2015-07-14 2017-01-18 上海拜豪生物科技有限公司 一种镉螯合型免疫复合物及其制备方法和应用
TWI747843B (zh) 2015-10-02 2021-12-01 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
EP3368568B1 (de) 2015-10-29 2022-04-06 F. Hoffmann-La Roche AG Anti-variante von fc-regionsantikörpern und verfahren zur verwendung
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
WO2017210621A1 (en) 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
EP3469001A4 (de) 2016-06-09 2020-05-06 Seattle Genetics, Inc. Kombinationen von pbd-basierten antikörper-arzneimittel-konjugaten mit flt3-inhibitoren
USD800912S1 (en) 2016-06-17 2017-10-24 Abreos Biosciences, Inc. Point-of-care diagnostic device
EP3497444A4 (de) 2016-08-12 2020-11-11 Abreos Biosciences, Inc. Nachweis und quantifizierung von natalizumab
WO2019067526A1 (en) 2017-09-26 2019-04-04 Poet Research, Inc. SYSTEMS AND METHODS FOR TREATING LIGNOCELLULOSIC BIOMASS
WO2022225575A1 (en) * 2021-04-21 2022-10-27 Siemens Healthcare Diagnostics Inc. Compositions, kits, and methods for anti-microbial serology assays using anti-human immunoglobulin antibody
WO2023081898A1 (en) * 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5426029A (en) * 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5059522A (en) 1988-08-18 1991-10-22 Wayne Lawrence G Intrinsic enzyme dot blot immunoassay or indentification of microorganisms
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
DE69033295T2 (de) * 1989-11-03 2000-05-25 Donald L Morton Nachweismethode für Harnkarzinom-assoziierte Antigene
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
US5726064A (en) 1990-11-22 1998-03-10 Applied Research Systems Ars Holding Nv Method of assay having calibration within the assay
US5234816A (en) * 1991-07-12 1993-08-10 Becton, Dickinson And Company Method for the classification and monitoring of leukemias
US5525461A (en) * 1991-11-01 1996-06-11 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using total leukocyte surface antigens
US5597735A (en) 1992-05-11 1997-01-28 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Health And Welfare Glycolipids for serodiagnosis of tuberculosis and leprosy
PT752248E (pt) * 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5667981A (en) * 1994-05-13 1997-09-16 Childrens Hospital Of Los Angeles Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
WO2000039580A1 (en) * 1998-12-23 2000-07-06 University Of Sydney An assay to detect a binding partner
ATE443259T1 (de) 2001-09-20 2009-10-15 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests

Also Published As

Publication number Publication date
US9157916B2 (en) 2015-10-13
US20160069902A1 (en) 2016-03-10
DE60233744D1 (de) 2009-10-29
US20140011215A1 (en) 2014-01-09
JP5781014B2 (ja) 2015-09-16
US20120107846A1 (en) 2012-05-03
EP1438583A2 (de) 2004-07-21
US20110236994A1 (en) 2011-09-29
JP2012198232A (ja) 2012-10-18
EP2131198A2 (de) 2009-12-09
WO2003024993A2 (en) 2003-03-27
US8114618B2 (en) 2012-02-14
EP2131198B1 (de) 2013-03-27
US7718387B2 (en) 2010-05-18
EP1438583B1 (de) 2009-09-16
US8501423B2 (en) 2013-08-06
JP2005533236A (ja) 2005-11-04
WO2003024993A3 (en) 2003-10-16
JP2014089213A (ja) 2014-05-15
AU2002327037A1 (en) 2003-04-01
US20100221761A1 (en) 2010-09-02
JP4424987B2 (ja) 2010-03-03
US20190041399A1 (en) 2019-02-07
JP2009075139A (ja) 2009-04-09
JP5264522B2 (ja) 2013-08-14
US7943332B2 (en) 2011-05-17
US20130004977A1 (en) 2013-01-03
US20140335549A1 (en) 2014-11-13
EP2131198A3 (de) 2010-07-07
US10018638B2 (en) 2018-07-10
US20180045736A1 (en) 2018-02-15
US8790882B2 (en) 2014-07-29
HK1068411A1 (en) 2005-04-29
EP1438583A4 (de) 2006-05-17
US20030068664A1 (en) 2003-04-10
US8232068B2 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
ATE443259T1 (de) Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
EA200500643A1 (ru) Способ неконкурентного иммуноанализа для определения малых аналитов
DK1139101T3 (da) Immunobestemmelse for C-reaktivt protein
ATE406578T1 (de) Candida-nachweis
RU2005131842A (ru) Моноклональное антитело и продуцирующая его гибридома
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
ATE554390T1 (de) Verfahren zur gewinnung von antikörpern
RU2001132335A (ru) Способ оценки наличия риска пептической язвы, включающий в себя этапы количественного определения концентрации пепсиногена i (pgi) и гастрин-17 в образце сыворотки
CA2589054A1 (en) Detection of a therapeutic antibody in an experimental animal
CN101042402A (zh) 用于癌症诊断的自身抗体检测
JP4918556B2 (ja) サンプル中の被検体（抗原）および該被検体を標的とする治療用抗体を同時に免疫化学的に測定するためのイムノアッセイ（リカバリー・イムノアッセイ（ＲｅｃｏｖｅｒｙＩｍｍｕｎｏａｓｓａｙ））
ATE519108T1 (de) Detektion von analyten in fäkalproben
Grebenchtchikov et al. An ELISA avoiding interference by heterophilic antibodies in the measurement of components of the plasminogen activation system in blood
EP1476757A4 (de) Verfahren und kit zur krebsvorhersage
WO2001075449A1 (fr) Technique d'investigation du cancer par epreuve biologique d'un autoanticorps contre mdm2 et reactif
JP4065600B2 (ja) 免疫学的測定法および免疫学的測定用キット
EP1347298A3 (de) Immunologisches Verfahren, Teststreifen und Vorrichtung
DK0991945T3 (da) Fremgangsmåde til identifikation af tumor-antigener med antistoffer i serum
DK1386160T3 (da) Fremgangsmåde til påvisning af blodcelle-antigener og antistoffer rettet mod disse
ATE481644T1 (de) Prognose des verlaufs einer krebserkrankung
ATE172543T1 (de) Frühdiagnose von sepsis unter verwendung von durch vollblut-chemilumineszenz verstärkten antigen-antikörper wechselwirkungen
FI980863A (fi) Menetelmä juoman ylikuohuntatekijän määrittämiseksi
WO2003101176A3 (en) Method, composition and kit for antigenic binding of norwalk-like viruses
JP4413371B2 (ja) Ｐｓａの測定方法及びその試薬
ES2189254T3 (es) Dosificado inmunologico que permite detectar los anticuerpos igm especificos del citomegalovirus humano.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties